INCYTE CORPORATION FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $5.1B |
| Gross margin | 92.8% |
| Operating income | $1.5B |
| Net income | $1.3B |
| Diluted EPS | $6.41 |
| Cash & equivalents | $3.1B |
| Total assets | $7.0B |
| Long-term debt | — not reported |
Key takeaway
Incyte reported $5.14 billion in revenue and $1.29 billion in net income for fiscal 2025, driven by its JAKAFI and OPZELURA franchises.
🔒 4 more takeaways in the full analysis
Beneath the surface
The company reports a large deferred tax valuation allowance of $2.27 billion against gross deferred tax assets of $2.79 billion, suggesting substantial historical losses or uncertain future tax benefit realization not evident from headline net income.
🔒 3 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 7 more findings — plus insider trades, activist stakes, and 8-K events for INCY.
Read the full analysis free Free account · 5 full analyses included · no card required